Study of Acid Reflux Therapy for Children With Asthma - Full Text View

Sponsors and Collaborators:	Emory University American Lung Association Johns Hopkins University Nemours Children's Clinic University of Manitoba Washington University School of Medicine New York Medical College University of Vermont Ohio State University Baylor College of Medicine Duke University
Information provided by:	Emory University
ClinicalTrials.gov Identifier:	NCT00604851

Purpose

Gastroesophageal reflux (GER) is frequent in children with asthma, can induce bronchspasm, and increase airway reactivity. Children with asthma are often treated for GER with drugs to supress gastric acid production. However, this treatment is expensive, and with unproven benefit. The primary objective of this study is to conduct a multi-site, randomized, clinical trial to test the hypothesis that treatment of GER with lansoprazole, an approved proton pump inhibitor, will decrease the frequency of exacerbations in children with poorly controlled asthma. The study will include300 asthmatic children treated with inhaled corticosteroids, 6-16 years of age, with poor control defined by frequent symptoms, excessive beta agonist use, or frequent exacerbations. Participants will be randomly assigned to treatment with either lansoprazole or placebo for 6 months. The presence, severity, and relationship of GER to asthma symptoms will be determined with 24 hour esophageal pH monitoring, but randomization to treatment will not be influenced by the presence or severity of GER. The primary outcome measure is the proportion of participants who have exacerbations of asthma defined by diaries and interviews. Secondary outcome measures include asthma symptom and control scores, GER symptoms, lung function, and unscheduled health care contacts. Pre-defined subgroup analyses will examine the relationship between specific clinical features and the response to lansoprazole. Treatment response will also be evaluated with 3-hour post-dose plasma lansoprazole concentrations, and related to polymorphisms in CYP2C19, the cytochrome P450 pathway, and IL-1 beta, a pro-inflammatory cytokine. Tertiary studies will determine how the magnitude of GER impacts airways inflammation, as measured by the concentrations of H+ (pH) and NO in expired breath. The results of this trial sould have a major impact on the understanding and treatment of GER in children with asthma.

Condition	Intervention
Asthma	Drug: lansoprazole Drug: placebo

MedlinePlus related topics: Asthma GERD

Drug Information available for: Lansoprazole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Study of Acid Reflux Therapy for Children With Asthma

Further study details as provided by Emory University:

Primary Outcome Measures:

The proportion of participants who have exacerbations of asthma as defined by diaries and interviews. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

asthma symptom and control scores [ Time Frame: 6 months ] [ Designated as safety issue: No ]
GER symptoms [ Time Frame: 6 months ] [ Designated as safety issue: No ]
lung function [ Time Frame: 6 months ] [ Designated as safety issue: No ]
unscheduled heathcare contacts [ Time Frame: within 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	300
Study Start Date:	September 2006
Estimated Study Completion Date:	December 2011
Estimated Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: lansoprazole participants < 30 kg: 15 mg po once daily
Placebo: Placebo Comparator	Drug: placebo participants < 30 kg: 15 mg po once daily participants <= 30 kg: 30 mg po once daily

Eligibility

Ages Eligible for Study:	6 Years to 16 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:Age:

6-16 years
Asthma: Physician diagnosed asthma, mathacholine PC20<16 mg/ml, treatment with a stable dose of daily inhaled corticosteroid equivalent to 200 micrograms/day of fluticasone or greater for 8 weeks or longer
Poor asthma control: Use of beta-agonist for asthma symptoms twice/week or more, nocturnal awakening with asthma symptoms more than once per week, 2 or more emergency department, unscheduled physician visit, prednisone course, or hospitalizations for asthma in the past 12 months, Score of 1.5 or greater on the Juniper Scale of Recent Asthma Control
Absence of GERD symptoms: No symptoms clearly attributed to GER at the time of enrollment.

Exclusion Criteria:

Surgery: Previous anti-reflux or peptic ulcer surgery, previous tracheo-esophageal fistula repair
Pulmonary Function:FEV1 <60% predicted normal as measured immediately before methacholine bronchoprovocation. Methacholine bronchoprovocation limited to participants with an FEV1 >70% of predicted in accordance with FDA indication
Other major chronic illnesses: Any major chronic illness including but not limited to non-skin cancer, cystic fibrosis, bronchiectasis, myelomeningocele, sickle cell anemia, endocrine disease, congenital heart disease, congestive heart failure, stroke, severe hypertension, insulin-dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency states, significant neurodevelopmental delay or behavioral disorders or other conditions that would interfere with participation in the study.
Medication Use: Anti-reflux medication (proton pump inhibitors, H2 blockers, bethanecol, metaclopromide) within 1 month; Theophylline preparations, azoles, anti-coagulants, insulin, digitalis, any investigative drug within 2 months.
Drug allergy: Previous adverse effects from lansoprazole, other proton pump inhibitors or methacholine challenge.
Non-adherence: Inability or unwillingness of the legal guardian to provide consent or inability or unwillingness of the child to provide assent. Inability to swallow study medication. Inability to perform baseline measurements. Less than 80% completion of screening period diaries. Inability to contact by telephone. Intention to move out of the areqa within 6 months. No pregnancy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00604851

Contacts

Contact: Denise Whitlock

404-717-1733

denise_whitlock@oz.ped.emory.edu

Locations

United States, Georgia
Emory Childrens Center	Recruiting
Atlanta, Georgia, United States, 30322

Sponsors and Collaborators

Emory University

American Lung Association

Johns Hopkins University

Nemours Children's Clinic

University of Manitoba

Washington University School of Medicine

New York Medical College

University of Vermont

Ohio State University

Baylor College of Medicine

Duke University

Investigators

Principal Investigator:

William G Teague, MD

Emory University

More Information

Responsible Party:	Emory University ( W. Gerald Teague, MD )
Study ID Numbers:	SARCA, 5 U01 HL080433-02
Study First Received:	December 27, 2007
Last Updated:	January 17, 2008
ClinicalTrials.gov Identifier:	NCT00604851
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases
Hypersensitivity, Immediate

Asthma
Lansoprazole
Gastroesophageal Reflux
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immune System Diseases
Bronchial Diseases
Therapeutic Uses

Anti-Ulcer Agents
Gastrointestinal Agents
Enzyme Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009